Establishment of whole-process intelligent pharmaceutical care model for peritoneal dialysis patients / 中国药房

OBJECTIVE To develop a whole-process intelligent model of pharmaceutical care for peritoneal dialysis （PD） patients， and to provide a reference for clinical pharmacists to provide standardized PD pharmaceutical care. METHODS The pharmaceutical care mode of PD patients at home and abroad was investigated and analyzed. Based on the actual situation of the First Affiliated Hospital of Soochow University （hereinafter referred to as “our hospital”）， with “home→PD center outpatient→ inpatient department” as the main node， the recycling process of medication reconciliation was optimized. The whole-process intelligent pharmaceutical care model of PD was illustrated by improving the Chinese version of the drug-related problems （DRPs） classification tool， developing the corresponding pharmaceutical care process， and presenting specific cases. RESULTS Based on the medication therapy management （MTM） platform， our hospital had built a closed-loop PD whole-process intelligent pharmaceutical care model of “in-hospital pharmaceutical care （building document）-PD outpatient MTM-home pharmaceutical care （online App management）”. A “double cycle” workflow of “admission→discharge→outpatient” medication reconciliation cycle and “discovery-analysis-intervention-follow-up-record-evaluation” DRPs cycle was formed. CONCLUSIONS The establishment of the whole-process intelligent pharmaceutical care model for PD in our hospital provides experience for standardizing pharmaceutical care for PD patients， and can reduce DRPs.

STUDIES ON PHOTOSENSITIZING AGENTS OF TUMOR LOCALIZATION AND THERAPY II. STUDY ON THE NEW PHOTOSENSITIZING AGENT PSD-007 / 第二军医大学学报

Here were reported the preparation and physicochemical properties of a new hema-toporphyrin photosensitizer PSD-007 and its selective uptake in tumor and the efficiency of experimental photolocalization and photoradiation therapy of Sarccma S180 bearing mice.The high photosensitizing PSD-007 with constant composition was prepared from hcmatoporphyrin photosensitizer PSD-001 by the removal of nearly 70% of its low PBT effect components.In comparison with US HPD, the amount of PSD-007 retained in tumor at the different intervals following iv injection was twice that of HPD showing excellent selective tumor PRT effect.In the tumor tissue of sarcoma S180 bearing mice which received an iv injection of 5-10 mg/kg body weight of PSD-007 appeared a bright orange fluorescene and thus it was clearly distinguished from the normal tissues around it at 24 and 48 hrs after injection on exposure to UV light and argon ion laser respectively. And when argon laser irradiation was applied for 20 min, it becomes ecchymosis, partial sclerosis, smoo-thening, and hollow around the center or partial slough after 24 hrs. This showed the reliable effect of experimental photolocalization and photoradiation therapy of tumors.The principal pharmacokinetic parameters of PSD-007 following iv injection to rabbits were also reported which provided a possible reference guide for the resonable administration of this drug in clinical practice.

Distribution of Hematoporphyrin Monomethyl Ether in Tumor-bearing Mice / 第二军医大学学报

spleen(?)heart(?)muscle.The pharmacokinetics of PsD-044 in mice was fitted by an open three compartment model. The pharmacokinetic parameters calculated were shown to be essentially consistent with the determination of tissue distribution. It was also shown that PsD-044 can't pass through blood-brain barrier.

STUDIES ON PHOTOSENSITIVE DRUGS OF LOCALIZATION AND PHOTOTHERAPY OF MALIGNANT TUMORS I. STUDY ON THE PHQTOSENSITIZER HEMATOPORPHYRIN / 第二军医大学学报

An improved method for the preparation of photosensitizer hematophorphy-rin with hemin from anticoagulated fresh swine or ox blood was reported.The results of UV and IR absorption spectra, fluorescence spectra, and TLC analysis showed that the photosensitizer hematoporphyrin prepared in such a way was the same as reported.The aqueous sodium salt of photosensitizer hematoporphyrin is unstable.A new peak of emission fluorescence spectra (640 nm) appeared at the same excited wave length (395 nm) on exposure to sun light.This indicated the presence of photolytic product of the photosensitizer.The experiment of the kinetics of the drug showed that it is unstable both to light and heat.The fluorescence decay of the aqueous sodium salt of hematoporphyrin photosensitizer in accordance with the pattern of first-order reaction of kinetics.The results of biological test showed marked photo-inactivity of human carcinoma cell lines of different species in vitro,and the ability in detection and phototherapy of sarcoma 180 (solid) tumor in mice.

Studies on Separation and Identification of the Components as well as the Tu- mor-photobiological Activities of the Major Components of Photocarcinorin / 第二军医大学学报

The chemical composition, separation and identification of the components as well as the tumor photobiological activities of the major components of the new tumor-photochemodiagnostic and photochemotherapeutic agent photocarcinorin (PsD-007) were represented in this paper. It has been shown by the results of HPLC analysis in combination with spectroscopic determinations that PsD-007 is composed of 7 different porphyrins: MHD, DMD, MVD, AHD, HVD, Hp and Pp. The experimental results show that MHD, DMD and MVD are the major tumor photobiologically active components of PsD-007.

STUDIES ON THE CHEMISTRY OF PHOTOCARCINQRIN / 第二军医大学学报

The preparation,chemical composition and physicochemical properties of photocar-cinorin (PsD-007),a new drug of photolocalizaion and photochemotherapy for human malignancies,are reported here.It has been shown by the resul s of thin layer and high performance liquid chromatographic (TLC & HPLC) analyses that about 85% of its total weight are relatively hydrophobic porphyrins of unknown structure in which a fraction with the same retention time as .hematoporphyrin(Hp)monoacetate constituts over 60%.There are also 4.2% of Hp,8.6% of 3(8) hydroxycthy lS-(3)-vinyldcutero-porphyrin (HVD) and 0.6% of portoporphyrin (Pp) in this drug.The presence and amount of HVD in PsD-007 were determined by an authentic sample prepared in our laboratory.The changes of the composition of PsD-007 on exposure to different doses of argon laser (488+ 514.5nm) were detected by HPLC.The variations in Soret peak of UV absorption spectra of PsD-007 protected from light at a constant temperature were also determined